Melanoma Associated Antigen 100+ / 7 kDa Mouse mAb

Catalog No.: F3175

Application: Reactivity: Human

Usage Information

Dilution
IHC1:5 - 1:20

Application
IHC, FCM

Reactivity
Human

Source
Mouse

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Datasheet & SDS

Biological Description

Specificity
Melanoma Associated Antigen 100+ / 7 kDa Mouse mAb detects endogenous levels of total Melanoma Associated Antigen 100+ / 7 kDa protein.

Clone
G24P23

Synonym(s)
MAA

Background
Melanoma Associated Antigen 100+ / 7 kDa (MAGE) proteins are tumor-associated antigens, typically restricted to germ cells of the testis in normal adult tissues but aberrantly expressed in various cancers, including melanoma, glioma, lung, bladder, and multiple myeloma. The “100+/7 kDa” designation refers to variants or isoforms with molecular weights around 100 kDa and 7 kDa. Structurally, MAGE proteins share a conserved ~200 amino acid MAGE homology domain (MHD) composed of two winged helix domains forming a deep cleft for peptide or protein binding, flanked by variable N- and C-terminal regions. Functionally, MAGE proteins can act as oncogenic drivers by interacting with RING-type E3 ubiquitin ligases, modulating protein degradation pathways that regulate apoptosis, proliferation, and metabolism; for example, MAGE-A3 promotes tumor survival by stimulating TRIM28-mediated p53 degradation, whereas MAGE-A4 may induce apoptosis via different protein partners. Their tumor-specific expression, structural plasticity, and oncogenic roles make MAGEs both biomarkers and potential therapeutic targets in cancer immunotherapy.

Background

Melanoma Associated Antigen 100+ / 7 kDa (MAGE) proteins are tumor-associated antigens, typically restricted to germ cells of the testis in normal adult tissues but aberrantly expressed in various cancers, including melanoma, glioma, lung, bladder, and multiple myeloma. The “100+/7 kDa” designation refers to variants or isoforms with molecular weights around 100 kDa and 7 kDa. Structurally, MAGE proteins share a conserved ~200 amino acid MAGE homology domain (MHD) composed of two winged helix domains forming a deep cleft for peptide or protein binding, flanked by variable N- and C-terminal regions. Functionally, MAGE proteins can act as oncogenic drivers by interacting with RING-type E3 ubiquitin ligases, modulating protein degradation pathways that regulate apoptosis, proliferation, and metabolism; for example, MAGE-A3 promotes tumor survival by stimulating TRIM28-mediated p53 degradation, whereas MAGE-A4 may induce apoptosis via different protein partners. Their tumor-specific expression, structural plasticity, and oncogenic roles make MAGEs both biomarkers and potential therapeutic targets in cancer immunotherapy.

References
https://pubmed.ncbi.nlm.nih.gov/26910052/ https://pubmed.ncbi.nlm.nih.gov/23946777/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%